Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential
Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term. Read why MEDP stock is a Strong Buy.
OmniAb (OABI) Gets a Buy from RBC Capital
In a report released on February 4, Conor McNamara from RBC Capital maintained a Buy rating on OmniAb (OABI – Research Report), with a price ...
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
RBC Capital analyst Conor McNamara maintained a Buy rating on QuidelOrtho (QDEL – Research Report) on February 4 and set a price target of ...
energydigital13h
Thermo Fisher: Powering Sites with 100% Renewable Energy
ELIO, Thermo Fisher Scientific is closer to its goal of powering its European sites with 100% renewable energy ...